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Mutations in any of the three genes coding for the extracel-
lular matrix protein collagen VI cause different types of muscle 
diseases, including Bethlem Myopathy (BM), Ullrich Congeni-
tal Muscular Dystrophy (UCMD) and Congenital Myosclero-
sis (1). Collagen VI null (Col6a1–/–) mice display a myopathic 
phenotype  with  organelle  defects,  mitochondrial  dysfunction 
and spontaneous apoptosis of muscle fibers (2). Based on the 
findings obtained in the murine model, similar defects could 
be  revealed  in  muscle  biopsies  and  cultures  of  UCMD/BM 
patients (3). Our previous studies demonstrated that one ma-
jor pathogenic event is the PTP-dependent latent mitochondrial 
dysfunction (4), however the cause for the accumulation of dys-
functional organelles remained unsolved.
The presence of swollen mitochondria and dilated sarco-
plasmic reticulum prompted to check whether the machinery 
for organelle removal, the autophagic system, is affected. We 
found that persistence of abnormal organelles and apoptosis are 
caused by defective autophagy in collagen VI deficient mus-
cles. Autophagy is a process of cytosolic ‘renovation’, which 
is essential for the maintenance of cell homeostasis by clear-
ing misfolded proteins and dysfunctional organelles. Skeletal 
muscles of Col6a1–/– mice display impaired autophagic flux, 
which matches the lower induction of Beclin 1 and Bnip3 and 
the  lack  of  autophagosomes  after  starvation.  Furthermore, 
muscle  biopsies  from  patients  affected  by  UCMD  or  BM 
show reduced levels of Beclin 1 and Bnip3. Notably, forced 
reactivation of autophagy by either genetic (overexpression 
of Beclin-1), nutritional (low protein diet) or pharmacologi-
cal (cyclosporin A) approaches restores myofiber survival and 
leads to a marked amelioration of the structural and functional 
defects of Col6a1–/– muscles, with normalization of the dys-
trophic phenotype (5, 6)
These  findings  indicate  that  defective  activation  of  the 
autophagic machinery has a key pathogenic role in congenital 
muscular dystrophies linked to collagen VI deficiency. Altogeth-
er, our data are the first demonstration that impaired autophagy 
plays a pivotal role in the pathogenesis of some muscular dys-
trophies, thus providing new insights into the pathogenesis of 
muscle degeneration and opening new perspectives for treat-
ment.
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A multidisciplinary referral clinic for the diagnosis and 
management  of  adult  patients  with  inflammatory  myopathy 
has been in operation at the ANRI in Perth since 1990. Patients 
are seen jointly by a neurologist, a clinical immunologist and 
physiotherapist and by a speech pathologist if they have swal-
lowing problems. The diagnosis of myositis is confirmed by 
muscle biopsy in all cases and screening for muscle-associated 
and muscle-specific autoantibodies is also performed. Over 250 
patients have been seen in the clinic, falling into the follow-
ing categories: inclusion body myositis (32%), dermatomyositis 
(32%), overlap syndromes (23%), isolated polymyositis (11%), 
miscellaneous (2%). Muscle function is monitored by manual 
muscle testing (MMT) and, in selected cases myometry and 
isokinetic dynamometry is performed. Patients undergo regu-
lar reviews to monitor the response to treatment. This has also 
allowed observations to be made on the frequency of relapses 
in patients with dermatomyositis and polymyositis (1), and the 
variability in the clinical phenotype and rate of progression of 
muscle  weakness  and  influence  of  HLA  alleles  in  inclusion 
body myositis (2). Two new clinical entities have been identi-
fied: statin-associated necrotising myopathy with upregulation 
of MHC-I (3), and a restricted scapulospinal form of myopathy 
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